Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner Sells 226 Shares

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner sold 226 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $11,910.20. Following the completion of the transaction, the chief accounting officer now directly owns 53,043 shares in the company, valued at $2,795,366.10. This represents a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Twist Bioscience Price Performance

Shares of TWST stock traded down $0.09 during trading on Tuesday, hitting $51.56. 627,617 shares of the stock traded hands, compared to its average volume of 941,410. Twist Bioscience Co. has a 52-week low of $26.51 and a 52-week high of $60.90. The firm has a market capitalization of $3.06 billion, a P/E ratio of -14.35 and a beta of 1.82. The firm’s fifty day moving average price is $44.49 and its 200-day moving average price is $46.51.

Institutional Trading of Twist Bioscience

Hedge funds have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $34,000. Signaturefd LLC lifted its holdings in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience during the 2nd quarter worth about $43,000. Blue Trust Inc. increased its holdings in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth about $61,000.

Analysts Set New Price Targets

TWST has been the subject of several recent research reports. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays lowered their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.